



BioMarker
STRATEGIES

News Release

Contact:

Scott Allocco, President

410-522-1008

sallocco@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

April 14, 2011 at 12 noon

BioMarker Strategies Awarded \$1 Million by National Cancer Institute

Baltimore, MD—April 14 —BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the final \$1 million in funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The SnapPath™ platform is being developed to assist oncologists in determining which targeted drug treatments will benefit their cancer patients. With this final grant of funds, the company has been awarded the entire \$2.3 million available under the contract.

"This funding has helped make our live tumor cell testing system a reality and we are thrilled to be given the opportunity to propel its development into the next phase," said Scott Allocco, President of BioMarker Strategies. "With initial SnapPath™ units scheduled for delivery this summer, we can now incorporate the technology into clinical trials to demonstrate the predictive value of live tumor cell testing in advanced melanoma and other cancers."

"I am pleased that BioMarker Strategies has leveraged the Maryland Biotech Tax Credit to win this federal funding," said Governor O'Malley. "Companies like BioMarker Strategies that harness the innovation, discovery, talents and skills of our people are what will move us forward and make our State a winner in the new economy."

This announcement comes at the heels of the company's recent appointment of Skip Klein to its Board of Directors. Klein is Managing Member of Gauss Capital Advisors, LLC, a life sciences investment advisory firm he founded in 1998. Prior to founding Gauss Capital Advisors, he was the Portfolio Manager and Chairman of the Investment Advisory Committee of the T. Rowe Price Health Sciences Fund. Klein has served on numerous biotechnology company boards, and was a founding partner of Red Abbey Venture Partners. He earned a B.A. in Economics, from Yale University, and an MBA, from Stanford University's Graduate School of Business.

BioMarker Strategies is developing the SnapPath™ system to enable next-generation predictive tests for cancer. The system incorporates an automated, live-tumor-cell processing device with first-in-class, functional, ex vivo biomarker tests to inform clinical decision making for targeted cancer therapeutics. SnapPath™ stimulates a patient's live tumor cells to obtain a Functional Signaling Profile (FSP™) of the signal transduction network that is not possible using static genomic biomarkers from dead, fixed tissue. The company is located at the Johns Hopkins Science + Technology Park in East Baltimore. For more information about BioMarker Strategies, please refer to www.biomarkerstrategies.com.

NEWS RELEASE

#

Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.

#